NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 13 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria shortened, about 6 words Show 4 more changesShow less
- Interventions modified
- Secondary endpoints: details revised at 3 of 12 entries
- Study description expanded, about 7 words
- Site details revised
- Minor Study description expanded, about 7 wordsv12
- Minor Start date changed from estimate of Sep 1, 2024 to Jul 23, 2024v11
- Notable Primary completion date: Oct 31, 2024 to Oct 31, 2031
- Study completion date: Oct 31, 2025 to Oct 31, 2032
- Start date: Aug 8, 2024 to Sep 1, 2024
- Notable Start date: Jul 6, 2024 to Aug 8, 2024v9
Show 7 earlier versionsHide 7 earlier versions
- Notable Start date: Jun 3, 2024 to Jul 6, 2024v8
- Notable Start date: May 3, 2024 to Jun 3, 2024v7
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: May 15, 2024 to May 3, 2024
- Site details revised
- Notable Start date: Mar 15, 2024 to May 15, 2024v5
- Minor Start date: Feb 15, 2024 to Mar 15, 2024v4
- Notable Eligibility criteria shortened, about 7 words
- Start date: Feb 6, 2024 to Feb 15, 2024
- Notable Start date: Jan 1, 2024 to Feb 6, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall survival
Timeframe: At 1 year
Secondary (12)
Cumulative incidence of neutrophil and platelet engraftment
Incidences of graft failure
Incidence of grade II-IV and III-IV acute graft-versus-host disease (aGVHD)
Incidence of grade II-IV and III-IV aGVHD
Incidence of chronic graft-versus-host disease (cGVHD)
Show 7 moreShow less
Organ distribution of GVHD
Incidence of adverse events
Time to immunosuppression cessation
Pattern of donor chimerism
Incidence of pre-engraftment syndrome (PES)
Incidence of transplant related mortality (TRM)
Incidence of relapse
Arms and interventions
Arm I (myeloablative UCBT)Experimental
See detailed description.
Arm II (myeloablative UCBT)Experimental
See detailed description.
Procedures: Biospecimen Collection, Bone Marrow Aspirate, Diagnostic Imaging Testing, Echocardiography Test, Multigated Acquisition Scan, Umbilical Cord Blood Transplantation
Drugs: Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Thiotepa
Other: Survey Administration
Radiation: Total-Body Irradiation
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States